METAVIA INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
METAVIA INC. (MTVA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents of $180.00 thousand as of 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents · last filed 2022-03-31
- 2021-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $180.00K.
- 2020-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $180.00K.
- 2019-12-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $1.52M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents |
|---|---|
| 2021-12-31 | $180.00K 10-K · filed 2022-03-31 |
| 2020-12-31 | $180.00K 10-K · filed 2021-04-15 |
| 2019-12-30 | $1.52M 10-K · filed 2021-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |